Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
Abstract Introduction Rapid improvement of psoriasis is valued by patients and should be considered to be an important factor in treatment selection. We investigated Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) response rates within the first 12 weeks of treatme...
Main Authors: | Richard B. Warren, Kyoungah See, Russel Burge, Ying Zhang, Alan Brnabic, Gaia Gallo, Alyssa Garrelts, Alexander Egeberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-11-01
|
Series: | Dermatology and Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s13555-019-00337-y |
Similar Items
-
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
by: Gisondi P, et al.
Published: (2016-05-01) -
Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
by: Martina Burlando, et al.
Published: (2021-05-01) -
Therapeutic Inertia in the Management of Moderate-to-Severe Plaque Psoriasis in Adolescents
by: Audrey Melin, et al.
Published: (2021-06-01) -
Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
by: Malakouti M, et al.
Published: (2016-10-01) -
Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021-01-01)